Located in Amsterdam, Genmed is focused on the delivery of low cost generic pharmaceutical drugs directly to distribution channels throughout the world. Today, Genmed took a major step towards prominence with the announcement of an expansion plan that will include a rollout to Scotland and Northern England.
The announcement comes on the heels of the January 20 press release that the company’s Irish distribution partner agreed to expand the corporation’s product rollout beyond Ireland.
In addition to the added territories, the distribution partner has also agreed to fund an advertising budget with Genmed’s products being placed within the distributor’s network of more than 1,200 pharmacies and over 150 hospitals throughout the world. This is great news for Genmed shareholders and the international medical community as a whole.
Leading the way at Genmed is Erwin Bouwens who serves as the company’s CEO. Commenting on what this expansion will mean to the future of Genmed, Bouwens was quoted as saying, “The addition of Scotland and Northern England to the rollout schedule is extremely exciting. This development shows the commitment of our distribution partner and expands our footprint in the United Kingdom.”
Currently, Genmed Holding Corp. is trading in the $0.50 range. To learn more about this up-and-coming corporation, visit the company website at: www.genmed.nl
About QualityStocks:
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment